Association of MTDH immunohistochemical expression with metastasis and prognosis in female reproduction malignancies: a systematic review and meta-analysis

• Published in: Scientific reports 2016-12, Vol.6 (1), p.38365-38365, Article 38365
• Main Authors: Hou, Yongbin, Yu, Lihua, Mi, Yonghua, Zhang, Jiwang, Wang, Ke, Hu, Liyi
• Format: Article
• Language: English
• Subjects: 13/51; 631/67/1347; 631/67/1857; 82/80; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cell Adhesion Molecules - genetics; Cervical cancer; Cervix; Data processing; Female; Females; Gene Expression; Health risk assessment; Humanities and Social Sciences; Humans; Immunohistochemistry; Lymph; Lymph nodes; Lymphatic Metastasis; Lymphatic system; Medical prognosis; Meta-analysis; Metastases; Metastasis; multidisciplinary; Ovarian cancer; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Prognosis; Science; Survival; Survival Analysis; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - mortality; Uterine Cervical Neoplasms - pathology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep38365

Various literatures have demonstrated that overexpression of Metadherin (MTDH) is correlated with tumor metastasis and it can predict poor survival outcomes in female reproduction malignancies. In order to enhance the statistical power and reach a recognized conclusion, we conducted a systematic review and meta-analysis to thoroughly investigate the association of MTDH expression with tumor metastasis and survival outcomes following PRISMA guidelines. Odds ratios (ORs) and hazard ratios (HRs) were used to demonstrate the impact of MTDH on tumor metastasis and prognosis respectively. Data were pooled with appropriate effects model on STATA12.0. Our results indicated that high MTDH expression is significantly correlated with higher mortality for breast, ovarian and cervical cancer. High immunohistochemical expression of MTDH is remarkably associated with shorter disease-free survival (DFS) in breast cancer but not in ovarian cancer. The pooled results suggested that high level of MTDH significantly predicted distant metastasis and lymph node metastasis in breast cancer. Strong associations were observed between MTDH expression and lymph node metastasis in ovarian and cervical cancer. In conclusion, MTDH might be a novel biomarker which can effectively reflect metastasis status and prognosis of breast cancer. However, its application in clinical practice needs more prospective studies with large samples.